Program to monitor surface contamination by methotrexate in a hematology-oncology satellite pharmacy

American Journal of Health-System Pharmacy

Volumn 64, Issue 5, 2007, Pages 531-535

  Bussières, Jean François ^a   Théorêt, Yves ^a   Prot Labarthe, Sonia ^a   Larocque, Diane ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Antineoplastic agents; Compounding; Contamination; Control, quality; Methotrexate; Pharmacy, institutional, hospital

Indexed keywords

METHOTREXATE;

ARTICLE; CANCER CHEMOTHERAPY; COMPUTER PROGRAM; CONTROLLED STUDY; DESORPTION; DRUG CONTAMINATION; DRUG LABELING; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHARMACY; PILOT STUDY; PRIORITY JOURNAL; SATELLITE PHARMACY;

EID: 33847406152     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060043     Document Type: Article

References (20)

1. Pharmaceutical compounding-sterile preparations (general information chapter 797). In: The United States pharmacopeia, 27th rev., and The national formulary, 22nd ed. Rockville, MD: United States Pharmacopeial Convention; 2004:2350-70.
2. National Institute for Occupational Safety and Health. NIOSH Alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. www.cdc.gov/niosh/docs/2004-165/pdfs/2004-165.pdf (accessed 2005 Oct 12).
3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. www.ashp.org/bestpractices/new/Haz_AJHP.pdf (accessed 2006 Dec 7).
4. Connor TH, Anderson RW, Sessink PJ et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm. 1999; 56:1427-32.
5. Selevan SG, Lindbohm ML, Hornung RW et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985; 313:1173-8.
6. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999; 20:347-59.
7. Sessink PJ, Kroese ED, van Kranen HJ et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995; 67:317-23.
8. Valanis BG, Vollmer WM, Labuhn KT et al. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993; 50:455-62.
9. Canadian Society of Hospital Pharmacists. Guidelines for the handling and disposal of hazardous pharmaceuticals (including cytotoxic drugs) 1997. www.cshp.ca/productsServices/official Publications/index_e.asp (accessed 2006 Dec 7).
10. Floridia L, Pietropaolo AM, Tavazzani M et al. High-performance liquid chromatography of methotrexate for environmental monitoring of surface contamination in hospital departments and assessment of occupational exposure. J Chromatogr B Biomed Sci Appl. 1999; 726:95-103.
11. Sessink PJ, Anzion RB, Van Den Broek PH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16-22.
12. Sessink PJ, Boer KA, Scheefhals AP et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105-12.
13. Crauste-Manciet S, Sessink PJ, Ferrari S et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005; 49:619-28.
14. Sessink PJ, Wittenhorst BC, Anzion RB et al. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997; 52:240-4.
15. Turci R, Sottani C, Spagnoli G et al. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 789:169-209.
16. Schulz H, Bigelow S, Dobish R et al. Antineoplastic agent workplace contamination study: the Alberta Cancer Board Pharmacy perspective. J Oncol Pharm Pract. 2005; 11:101-9.
17. Hemminki K, Kyyronen P, Lindbohm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health. 1985; 39:141-7.
18. Valanis B, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999; 41:632-8.
19. Valanis B, Vollmer W, Labuhn K et al. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997; 39:574-80.
20. Skov T, Maarup B, Olsen J et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992; 49:855-61.